Sigma Healthcare posts $1.09B FY26 EBIT following merger

• Sigma Healthcare recorded $1.09 billion in normalised earnings before interest and tax for FY26.
• The annual results reflect a 20.6% increase in earnings and a 15.5% lift in revenue.
• The business is driving market expansion via Chemist Warehouse store rollouts across domestic and global targets.

Sigma Healthcare (ASX:SIG) reported full-year revenue of $10.8 billion and normalised EBIT of $1.09 billion for the period ended June 30.

The outcome marks the company's first full financial year operating as a combined business following its merger with Chemist Warehouse Group.

Sales also have benefited from the structural uplift in consumption of GLP-1 medicines across the market.

“To put our progress in context, normalised pro forma EBIT for FY24 at the time of the merger, as disclosed in our prospectus, was $605.5 million; two years on, we have delivered normalised EBIT of almost $1.1 billion, up over 80%, with normalised EBIT margin growing from 9.6% in FY25 to 10.1% this year,” said Sigma Healthcare CEO & Managing Director Vikesh Ramsunder.

The company delivered $32.6 million in integration synergies during the period as net debt increased to $663 million.

The business stated that it remains on track to deliver $100 million in annual synergies by FY29.

The board has declared a fully franked final dividend of 2 cents per share, adding to the interim dividend of 2 cents per share paid in March.

"In H1 FY27, we will onboard 13 Chemist Warehouse branded stores across the Australian network, a similar cadence to prior years, and 19 Chemist Warehouse stores internationally, including our entry into the UK market," added Ramsunder.

Following the announcement, the Sigma Healthcare share price was down at $2.62.

The company oversees a global retail network approaching 1,000 pharmacies supported by Australian distribution infrastructure.